LeMaitre Vascular Inc (NASDAQ:LMAT) CEO George W. Lemaitre sold 2,000 shares of the company’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $32.54, for a total transaction of $65,080.00. Following the completion of the transaction, the chief executive officer now directly owns 3,135,730 shares in the company, valued at approximately $102,036,654.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
NASDAQ LMAT opened at $32.32 on Friday. The firm has a 50-day moving average of $29.07. LeMaitre Vascular Inc has a 12 month low of $21.79 and a 12 month high of $38.99. The firm has a market capitalization of $642.27 million, a PE ratio of 38.48, a P/E/G ratio of 3.80 and a beta of 1.14.
LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Wednesday, July 24th. The medical instruments supplier reported $0.23 EPS for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.02. LeMaitre Vascular had a net margin of 16.72% and a return on equity of 13.15%. The company had revenue of $29.48 million for the quarter, compared to analysts’ expectations of $28.90 million. During the same quarter in the prior year, the company posted $0.43 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, sell-side analysts expect that LeMaitre Vascular Inc will post 0.86 EPS for the current fiscal year.
A number of research analysts have commented on LMAT shares. First Analysis raised shares of LeMaitre Vascular from a “neutral” rating to an “outperform” rating and upped their target price for the company from $29.00 to $37.00 in a research report on Thursday, July 25th. ValuEngine raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Monday, July 22nd. Barrington Research reaffirmed an “outperform” rating and issued a $37.00 target price (up previously from $32.00) on shares of LeMaitre Vascular in a research report on Thursday, July 25th. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating and set a $38.00 target price on the stock in a research report on Saturday, July 27th. Finally, Lake Street Capital upped their target price on shares of LeMaitre Vascular from $27.00 to $34.00 and gave the company a “hold” rating in a research report on Thursday, July 25th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $35.33.
Large investors have recently modified their holdings of the business. BNP Paribas Arbitrage SA increased its stake in LeMaitre Vascular by 66,640.0% during the first quarter. BNP Paribas Arbitrage SA now owns 3,337 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 3,332 shares during the period. Municipal Employees Retirement System of Michigan purchased a new stake in LeMaitre Vascular during the fourth quarter worth about $106,000. Metropolitan Life Insurance Co. NY increased its stake in LeMaitre Vascular by 373.8% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 5,629 shares of the medical instruments supplier’s stock worth $133,000 after purchasing an additional 4,441 shares during the period. BB&T Corp purchased a new stake in LeMaitre Vascular during the first quarter worth about $203,000. Finally, Globeflex Capital L P increased its stake in LeMaitre Vascular by 26.5% during the first quarter. Globeflex Capital L P now owns 6,578 shares of the medical instruments supplier’s stock worth $204,000 after purchasing an additional 1,378 shares during the period. Institutional investors own 78.24% of the company’s stock.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.